| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues: |
| United States | 271.0 | 275.4 | 177.2 | 121.2 | 71.8 | | | |
| International | 178.1 | 146.7 | 107.0 | 81.3 | 61.8 | | | |
| Research collaboration | | 19.9 | 6.0 | | | | | |
| Total revenues | 449.1 | 422.1 | 284.2 | 202.4 | 133.7 | 86.3 | 67.6 | 37.1 |
| Revenue growth [+] | 6.4% | 48.5% | 40.4% | 51.4% | 54.9% | 27.6% | 82.4% | |
| United States | -1.6% | 55.4% | 46.2% | 68.7% | | | | |
| International | 21.4% | 37.1% | 31.7% | 31.4% | | | | |
| Research collaboration | | 234.0% | | | | | | |
| Cost of goods sold | 120.6 | 136.8 | 99.9 | 71.3 | 55.1 | 39.9 | 30.2 | 16.9 |
| Gross profit | 328.5 | 285.3 | 184.3 | 131.1 | 78.6 | 46.5 | 37.4 | 20.2 |
| Gross margin | 73.1% | 67.6% | 64.9% | 64.8% | 58.8% | 53.8% | 55.3% | 54.3% |
| Selling, general and administrative | 225.0 | 232.2 | 194.3 | 141.8 | 130.4 | 103.0 | 82.5 | 48.1 |
| Research and development | 49.1 | 48.8 | 48.4 | 26.7 | 39.3 | 38.9 | 45.1 | 33.0 |
| Equity in earnings | | | | | | | | -2.2 |
| Other operating expenses | 30.0 | 37.1 | 40.4 | 17.4 | 10.7 | 9.9 | 12.1 | 17.4 |
| EBITDA [+] | 60.7 | 9.8 | -70.1 | -37.5 | -87.0 | -90.2 | -86.1 | -63.1 |
| EBITDA growth | 521.3% | -113.9% | 86.7% | -56.8% | -3.6% | 4.8% | 36.4% | |
| EBITDA margin | 13.5% | 2.3% | -24.7% | -18.5% | -65.0% | -104.5% | -127.3% | -170.3% |
| Depreciation | 11.2 | 11.5 | 8.4 | | 4.1 | 5.2 | 4.1 | |
| EBITA | 49.5 | -1.8 | -78.5 | -37.5 | -91.1 | -95.5 | -90.2 | -63.1 |
| EBITA margin | 11.0% | -0.4% | -27.6% | -18.5% | -68.1% | -110.6% | -133.4% | -170.3% |
| Amortization of intangibles | 25.1 | 31.1 | 20.3 | 17.2 | 10.7 | 9.9 | 12.1 | 17.4 |
| EBIT [+] | 24.4 | -32.8 | -98.8 | -54.8 | -101.8 | -105.3 | -102.3 | -80.5 |
| EBIT growth | -174.2% | -66.8% | 80.4% | -46.2% | -3.4% | 3.0% | 27.0% | |
| EBIT margin | 5.4% | -7.8% | -34.8% | -27.1% | -76.1% | -122.0% | -151.2% | -217.1% |
| Non-recurring items [+] | | 299.3 | 70.7 | 1.8 | 1.1 | -14.4 | 0.5 | 104.2 |
| Asset impairment | | 299.3 | | | | | | |
| Loss (gain) on sale of assets | | | | | 0.2 | -14.4 | 0.0 | |
| In-process research & development | | | 70.7 | 1.8 | 0.9 | | 0.5 | 104.2 |
| Interest expense, net [+] | 0.8 | -0.2 | -1.9 | -1.7 | 9.9 | 25.4 | 12.7 | 1.1 |
| Interest expense | 0.8 | | | | 9.9 | 25.4 | 12.7 | 1.1 |
| Interest income | | 0.2 | 1.9 | 1.7 | | | | |
| Other income (expense), net [+] | 2.5 | -1.9 | 2.8 | 3.2 | 3.3 | 17.3 | 8.8 | 20.8 |
| Gain (loss) on investments | | | | | | -1.7 | -3.4 | -7.4 |
| Other | -1.6 | -2.4 | 2.9 | 2.1 | -3.4 | 1.8 | 1.6 | 0.2 |
| Pre-tax income | 26.1 | -333.8 | -164.8 | -51.7 | -109.5 | -99.1 | -106.6 | -165.0 |
| Income taxes | -15.8 | 1.8 | 0.9 | 0.7 | 0.5 | 0.2 | 0.3 | 0.2 |
| Minority interest | | | | | -2.0 | -13.8 | -3.8 | -13.3 |
| Net income | 41.9 | -335.6 | -165.7 | -52.4 | -110.0 | -99.3 | -106.9 | -165.2 |
| Net margin | 9.3% | -79.5% | -58.3% | -25.9% | -82.3% | -115.0% | -158.1% | -445.4% |
| |
| Basic EPS [+] | $0.39 | ($3.22) | ($2.37) | ($0.93) | | | | |
| Growth | -112.1% | 35.6% | 156.2% | | | | | |
| Diluted EPS [+] | $0.38 | ($3.22) | ($2.37) | ($0.93) | | | | |
| Growth | -112.0% | 35.6% | 156.2% | | | | | |
| |
| Shares outstanding (basic) [+] | 108.0 | 104.4 | 69.9 | 56.6 | | | | |
| Growth | 3.5% | 49.3% | 23.5% | | | | | |
| Shares outstanding (diluted) [+] | 109.0 | 104.4 | 69.9 | 56.6 | | | | |
| Growth | 4.4% | 49.3% | 23.5% | | | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |